Skip to main content

Manipulating cells with materials

March 22, 2017 - 3:00pm to 4:00pm
Jennifer West, Ph.D. , Duke University

Our research in biomaterials and tissue engineering involves the synthesis, development, and application of novel, biofunctional materials, and the use of biomaterials and engineering approaches to study biological problems

Unraveling Smell

March 29, 2017 - 3:00pm to 4:00pm
Linda B. Buck, Ph.D., Fred Hutchinson Cancer Research Center

Dr. Linda Buck is a Howard Hughes Medical Institute Investigator, a Full Member of Fred Hutchinson Cancer Research Center, and an Affiliate Professor at the University of Washington. She received a B.S. from the University of Washington and a Ph.D. from the University of Texas Southwestern Medical Center. She was previously Full Professor of Neurobiology at Harvard Medical School. Dr.

Stem cells, aging, and aging stem cells

April 5, 2017 - 3:00pm to 4:00pm
Amy Wagers, Ph.D. , Harvard University

Research in Dr. Wagers’s lab seeks to discover fundamental principles that govern tissue aging and determine stem cell function in organ regeneration and degenerative disease. These efforts build upon novel discoveries and unique experimental models, which are defining the cellular and molecular networks that control muscle regenerative activity and uncovering common signals delivered via the bloodstream that can reverse the effects of aging across tissues.

The split personality of human O-GlcNAc transferase

April 18, 2017 - 3:00pm to 4:00pm
Suzanne Walker, Ph.D. , Harvard University

O-GlcNAc Transferase (OGT) is a glycosyltransferase essential for the viability of most multicellular organisms, including mammals. It catalyzes the attachment of N-acetylglucosamine (GlcNAc) to serines and threonines of nuclear and cytoplasmic proteins, resulting in changes in protein localization, stability, and interactions. Protein O-GlcNAc levels are responsive to cellular glucose concentration, and chronically elevated O-GlcNAc levels are observed in both cancer and diabetes and are associated with widespread changes in gene expression.

From protein folding to cognition: a serendipitous path of discovery

April 19, 2017 - 3:00pm to 4:00pm
Peter Walter, Ph.D. , University of California, San Francisco

A screen for small molecule modulators of the unfolded protein response yielded ISRIB, a drug-like compound that with high efficacy renders cells insensitive to translational inhibition by phosphorylation of eIF2. ISRIB is an activator of eIF2B, eIF2’s guanine nucleotide exchange factor, and a cognitive enhancer in rodents, significantly improving long-term memory of wild-type animals in behavioral assays.

The primary shield: role of our microbes in health and diseases

April 26, 2017 - 3:00pm to 4:00pm
Yasmine Belkaid, Ph.D. , National Institute of Health, NIAID

Dr. Belkaid work explores the field of immune regulation and has defined fundamental mechanisms that regulate tissue homeostasis and host immune responses. Her work uncovered key roles for the commensal microbiota and dietary factors in the maintenance of tissue immunity and protection to pathogens.

The changing epidemiology of HPV and cervical cancer: from etiology, to validation of prevention methods, to dissemination

May 3, 2017 - 3:00pm to 4:00pm
Mark Schiffman, M.D., M.P.H., NCI-DCEG

Over three decades of studies moving from etiology to preventive methods research to guidelines development, Dr. Schiffman has learned some broad lessons about the strengths and weaknesses of epidemiology that he will describe.

Extracellular vesicles released by glioblastoma cells: saboteurs, biomarkers and therapeutics

May 10, 2017 - 3:00pm
Xandra O. Breakefield, Ph.D., Massachusetts General Hospital

Xandra Breakefield, Ph.D. is a basic scientist with a strong background in molecular genetics and neuroscience. She focuses her research efforts on: gene therapy for neurologic diseases; and elucidation of the role of extracellular vesicles (EVs) released from cancer cells in tumor progression. She led early studies demonstrating mutant RNA in serum EVs from glioblastoma patients as biomarkers. She did her undergraduate work at Wilson College and her graduate work in Microbial Genetics at Georgetown University. She was a Postdoctoral Fellow with Nobel Prize winner, Dr.

Brave new world: recent evolution of an insect-transmitted pathogen

May 17, 2017 - 3:00pm to 4:00pm
Roberto Kolter, Ph.D., Harvard Medical School

In their natural settings microbes seldom encounter conditions that are propitious for unrestricted growth. Rather, they must survive in environments where most of the time they are faced with limiting amounts of essential nutrients, stressful stimuli and the presence of other living organisms. Since the early 1980s, Dr. Kolter’s laboratroy has investigated many of these survival strategies using approaches from genetics, biochemistry and ecology.

How aneuploidy drives cancer

May 24, 2017 - 3:00pm to 4:00pm
Stephen J. Elledge, PhD, Harvard Medical School

Aneuploidy has been recognized as a hallmark of cancer for more than 100 years, yet no general theory has emerged to explain the recurring patterns of aneuploidy in cancer. Dr. Elledge's laboratory developed the Tumor Suppressor and Oncogene (TUSON) Explorer, a computational method that analyzes the patterns of mutational signatures in tumors and predicts the likelihood that any individual gene functions as a tumor suppressor gene (TSG) or an oncogene (OG).


The page was last updated on Monday, September 19, 2016 - 7:14pm